Temporal trends in the incidence of intermittent claudication from 1950 to 1999

American Journal of Epidemiology

Volumn 162, Issue 5, 2005, Pages 430-437

  Murabito, Joanne M ^a,b,e   Evans, Jane C ^a   D'Agostino Sr , Ralph B ^a,c   Wilson, Peter W F ^d   Kannel, William B ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e FRAMINGHAM HEART STUDY   (United States)

Author keywords

Cardiovascular diseases; Intermittent claudication; Mortality

Indexed keywords

CARDIOVASCULAR DISEASE;

ADULT; AGE DISTRIBUTION; ARTICLE; CALCULATION; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; INCIDENCE; INTERMITTENT CLAUDICATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE DISEASE; MUSCLE EXERCISE; POISSON DISTRIBUTION; REGRESSION ANALYSIS; REST; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL;

ADULT; FEMALE; HUMANS; INCIDENCE; INTERMITTENT CLAUDICATION; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MASSACHUSETTS; MIDDLE AGED; POISSON DISTRIBUTION; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 23944516594     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi217     Document Type: Article

References (47)

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
2. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality: The Whitehall Study. Circulation 1990;82:1925-31.
3. Bainton D, Sweetnam P, Baker I, et al. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 1994;72:128-32.
4. Bowlin SJ, Medalie JH, Flocke SA, et al. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol 1997;7:180-7.
5. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1996;1:60-4.
6. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004;292:453-61.
7. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985;33:13-18.
8. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997;96:44-9.
9. Bowlin SJ, Medalie JH, Flocke SA, et al. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol 1994;140:418-30.
10. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
12. From the Centers of Disease Control and Prevention. State-specific trends in high blood cholesterol awareness among persons screened - United States, 1991-1999. JAMA 2001;286:1706-7.
13. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
14. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction: The Framingham Heart Study. Circulation 1999;100:2054-9.
15. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
16. Collaborative meta-analysis of randomised trials of antiplate-let therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
17. Feinleib M, Kannel WB, Garrison RJ, et al. The Framingham Offspring Study: design and preliminary data. Prev Med 1975;4:518-25.
18. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families: The Framingham Offspring Study. Am J Epidemiol 1979;110:281-90.
19. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: The Framingham Study. Am J Public Health 1951;41:279-81.
20. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: The Framingham Study. Ann N Y Acad Sci 1963;107:539-56.
21. SAS/STAT software: changes and enhancements through release 6.12 PROC GENMOD. Cary, NC: SAS Institute, Inc, 1997:247-38.
22. Ingolfsson IO, Sigurdsson G, Sigvaldason H, et al. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol - The Reykjavik Study. J Clin Epidemiol 1994;47:1237-43.
23. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998;279:119-24.
24. van den Berkmortel FW, Smilde TJ, Wollersheim H, et al. Intima-media thickness of peripheral arteries in asymptomatic cigarette smokers. Atherosclerosis 2000;150:397-401.
25. Fox CS, Evans JC, Larson MG, et al. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: The Framingham Heart Study. Circulation 2004;110:522-7.
26. McGovern PG, Shafar E, Sprafka JM, et al. The role of stroke attack rate and case fatality in the decline of stroke mortality: The Minnesota Heart Survey. Ann Epidemiol 1993;3:483-7.
27. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality: The Framingham Study. Stroke 1992;23:1551-5.
28. McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med 2002;17:895-904.
29. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157-62.
30. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
31. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
32. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-5.
33. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 1998;(4):CD000123. (Electronic article). (http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/ CD000123/frame.html).
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
35. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
36. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-6.
37. Dagenais GR, Maurice S, Robitaille NM, et al. Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study. Clin Invest Med 1991;14:93-100.
38. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331-40.
39. Fowler B, Jamrozik K, Norman P, et al. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers. Aust N Z J Public Health 2002;26:219-24.
40. Greenlund KJ, Zheng ZJ, Keenan NL, et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med 2004;164:181-8.
41. Newman AB, Sutton-Tyrrell K, Kuller LH. Lower-extremity arterial disease in older hypertensive adults. Arterioscler Thromb 1993;13:555-62.
42. Collins TC, Petersen NJ, Suarez-Almazor M, et al. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003;163:1469-74.
43. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002;143:961-5.
44. Newman AB, Sutton-Tyrrell K, Rutan GH, et al. Lower extremity arterial disease in elderly subjects with systolic hypertension. J Clin Epidemiol 1991;44:15-20.
45. Vogt MT, Cauley JA, Kuller LH, et al. Prevalence and correlates of lower extremity arterial disease in elderly women. Am J Epidemiol 1993;137:559-68.
46. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599-606.
47. Newman AB, Naydeck BL, Sutton-Tyrrell K, et al. The role of comorbidity in the assessment of intermittent claudication in older adults. J Clin Epidemiol 2001;54:294-300.